Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP) (clinical trial identifier: NCT04724980). The US Food and Drug Administration recently granted Orphan Drug Designation for PRGN-2012 in RRP in March 2021.